Subject category:
Strategy and General Management
Published by:
Ivey Publishing
Version: 2021-02-12
Length: 11 pages
Data source: Published sources
Abstract
In July 2020, Eastman Kodak Company (Kodak) received a USD765 million loan from the US federal government for drug component manufacturing. Kodak's chief executive officer (CEO) was confident about the company's ability to excel in the pharmaceutical industry. However, critics cited several concerns, such as workforce availability and Kodak's lack of experience in the pharma business. The CEO believed that Kodak's expertise in advanced chemicals and manufacturing could drive the firm's success in the pharma business. Would Kodak be able to establish its mark in the US pharma industry? What challenges was Kodak likely to face?
Teaching and learning
This item is suitable for undergraduate and postgraduate courses.About
Abstract
In July 2020, Eastman Kodak Company (Kodak) received a USD765 million loan from the US federal government for drug component manufacturing. Kodak's chief executive officer (CEO) was confident about the company's ability to excel in the pharmaceutical industry. However, critics cited several concerns, such as workforce availability and Kodak's lack of experience in the pharma business. The CEO believed that Kodak's expertise in advanced chemicals and manufacturing could drive the firm's success in the pharma business. Would Kodak be able to establish its mark in the US pharma industry? What challenges was Kodak likely to face?